financetom
Business
financetom
/
Business
/
Brookfield Seals The Deal: Snags Major Stake In French Powerhouse Neoen
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brookfield Seals The Deal: Snags Major Stake In French Powerhouse Neoen
Jun 25, 2024 6:31 AM

Brookfield Asset Management Ltd. ( BAM ) disclosed signing a share purchase agreement for a majority stake in France’s Neoen.

This transaction, known as the “Block Acquisition,” was signed after Neoen completed its works council information and consultation process.

As announced earlier, Brookfield’s offer implies an equity value of 100% of the shares of EUR 6.1 billion.

In particular, Brookfield inked a share purchase agreement with Impala, the Fonds Stratégique de Participations managed by ISALT, Cartusia, Xavier Barbaro, and other shareholders to acquire approximately 53.12% of Neoen’s outstanding shares for EUR 39.85 per share.

In addition, Brookfield entered into a tender agreement with Bpifrance’s ETI 2020 fund. Bpifrance agreed to tender its 4.36% stake in Neoen in Brookfield’s upcoming tender offer following the completion of the Block Acquisition.

Notably, in May, Brookfield Asset Management ( BAM ), together with its institutional partners, including Brookfield Renewable Partners ( BEP ) and Temasek, through a special purpose vehicle, inked an exclusive negotiation to acquire a 53.32% shareholding in Neoen.

The completion of the Block Acquisition is contingent upon customary regulatory approvals, including antitrust and foreign investment clearances.

Subject to the closing of the Block Acquisition, it is expected that Brookfield would file an all-cash mandatory tender offer for all of the remaining shares and outstanding convertible bonds in Neoen, with the intention of implementing a squeeze out. 

The company expects to obtain regulatory approvals by the fourth quarter of 2024, with the tender offer expected to commence in the first quarter of 2025.

As of March-end, BAM had cash and cash equivalent of $2.6 billion.

Price Action: BAM shares are up 0.68% at $38.54 premarket at the last check Tuesday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Monday.com Q4 Non-GAAP Earnings, Revenue Increase; Q1, 2025 Sales Guidance Issued
Monday.com Q4 Non-GAAP Earnings, Revenue Increase; Q1, 2025 Sales Guidance Issued
Feb 10, 2025
07:31 AM EST, 02/10/2025 (MT Newswires) -- Monday.com ( MNDY ) reported Q4 non-GAAP net income Monday of $1.08 per diluted share, up from $0.65 a year earlier. Analysts polled by FactSet expected $0.79. Revenue for the quarter ended Dec. 31 was $268 million, up from $202.6 million a year earlier. Analysts surveyed by FactSet expected $261.4 million. For Q1,...
Market Chatter: OpenAI Planning to Finalize In-House Chip Design in Coming Months
Market Chatter: OpenAI Planning to Finalize In-House Chip Design in Coming Months
Feb 10, 2025
07:33 AM EST, 02/10/2025 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI plans to finalize the design for its first in-house chip in the coming months as it looks to lessen its dependence on Nvidia (NVDA) for chip supply, Reuters reported Monday, citing unnamed sources familiar with the matter. OpenAI then plans to send the chip design to Taiwan...
Gabon launches tender offer for $315 mln outstanding on 2025 Eurobond
Gabon launches tender offer for $315 mln outstanding on 2025 Eurobond
Feb 10, 2025
NAIROBI, Feb 10 (Reuters) - Gabon launched an offer to repurchase, at face value, the $315 million outstanding on its 2025 Eurobond maturing in June, it said in a document published on Monday. The government also said it will also sell new dollar-denominated notes through private placement. In November, Gabon said it had closed a deal to buy back $290...
Bristol-Myers Squibb Says Cancer Therapy Trial Meets Primary, Secondary Goals
Bristol-Myers Squibb Says Cancer Therapy Trial Meets Primary, Secondary Goals
Feb 10, 2025
07:30 AM EST, 02/10/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday its phase 2 trial evaluating Breyanzi in adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary endpoint in the marginal zone lymphoma cohort. Marginal zone lymphoma is the second most common, slow-growing form of non-Hodgkin lymphoma when white blood cells cluster together to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved